Owkin becomes the latest French unicorn after a $180M investment from Sanofi

Media article at sifted.eu

‍

About Owkin

Owkin is an agentic AI company on a mission to explore complex biology to speed up and scale research for the creation of new treatments and diagnostics for patients. Owkin K, our AI co-pilot combines unparalleled access to multimodal data, cutting-edge AI to quantify biology and pioneering agentic AI to achieve Biological Artificial Superintelligence in the future.

Press Kit

More like this

In the media

Wall Street Journal features CEO Thomas Clozel

February 10, 2025

In the media

EY features Owkin's CEO Thomas Clozel in the "Grow Fast, Now What?" podcast (FR)

February 18, 2025